Albendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed mice.
AUTOR(ES)
Bartlett, M S
RESUMO
Albendazole, a benzimidazole derivative widely used for treating helminth infections, was successfully used to treat and prevent development of Pneumocystis carinii pneumonia in transtracheally inoculated immunosuppressed mice. For treatment, 3 weeks postinoculation, albendazole at 300 and 600 mg/kg of body weight per day was administered in food for 3 weeks. For prophylaxis, albendazole was begun on the same day as inoculation at 300 mg/kg/day for 7 days, and then the dose was reduced to 150 mg/kg/day for 35 additional days. With these regimens, albendazole was effective both for treatment and prophylaxis. Both dexamethasone-immunosuppressed and L3T4+ monoclonal antibody-immunosuppressed mouse models were used, and albendazole inhibited P. carinii infection in both.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=284645Documentos Relacionados
- Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs.
- Outbreaks of Pneumocystis carinii pneumonia in colonies of immunodeficient mice.
- Experimental Pneumocystis carinii pneumonia in different strains of cortisonized mice.
- Active immunity to Pneumocystis carinii reinfection in T-cell-depleted mice.
- Guanylhydrazones in therapy of Pneumocystis carinii pneumonia in immunosuppressed rats.
